IDHIFA
Author: Rachael Lloyd
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
IDHIFA is an oral selective reversible inhibitor of the mutant form of the IDH2 enzyme that is associated with a wide range of cancers, including approximately 8–12% of AML cases. Mutant IDH2 is linked to the over-production of the metabolite D-2-hydroxygluterate, which inhibits cellular differentiation and can lead to the transformation of cancerous cells (Agios Pharmaceuticals, 2016).
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 IDHIFA : Acute myeloid leukemia (AML)
LIST OF FIGURES
10 Figure 1: IDHIFA for acute myeloid leukemia – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of IDHIFA for acute myeloid leukemia
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of IDHIFA for acute myeloid leukemia
LIST OF TABLES
5 Table 1: IDHIFA drug profile
7 Table 2: IDHIFA Phase III trial in acute myeloid leukemia
9 Table 3: IDHIFA Phase I/II data in acute myeloid leukemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Iomab-B 
Sign up to the